Philippines Cheaper Medicines Act Sees More Delay
This article was originally published in PharmAsia News
The Cheaper Medicines Act in the Philippines Legislature has suffered another delay in gaining final passage. The speaker of the House of Representatives has held back on a vote to pass the bill because he wants to make sure the measure would do what is intended, "really bring down the cost of medicines." Speaker Prospero Nograles said he wants to take a personal look at the measure, but a trip he has planned would delay his review for at least a week. The House and Senate remain divided over the government body to be given authority to regulate drug prices. (Click here for more
You may also be interested in...
Novartis seems to have accepted the fact that the indication granted for Piqray in the EU means there is little scope for the advanced breast cancer drug to be used in markets such as the UK.
Generic OTC paracetamol and ibuprofen pack prices are gradually returning to pre-COVID levels, according to market analysts Wavedata. But a second wave could drive prices back up again.
Latest EU company news: Sanofi grows OTC portfolio in France and Italy with ColdZyme; Germany's WindStar Medical gets UK owners; and France's Ipsen continues to fell effects of COVID-19 on sales.